OrbiMed

Congrats to our portfolio company, SpringWorks Therapeutics, on receiving FDA approval for GOMEKLI, a MEK inhibitor, for treating adults and children with neurofibromatosis type 1-associated plexiform neurofibromas. This approval is a testament to the hard work and dedication of the SpringWorks team, following the successful Phase 2b ReNeu trial that showed promising results in tumor volume reduction and safety, making a meaningful impact on patients' lives.

OrbiMed is excited to announce our $35M investment in vVARDIS to support the global expansion of Curodont, a revolutionary drill-free treatment for early tooth decay. This partnership highlights our shared vision of providing innovative solutions in a global market.  https://lnkd.in/eJ6gBEj2

Congratulations to our portfolio company Sionna Therapeutics! The clinical-stage biotech company advancing innovative cystic fibrosis therapies raised $191M in its upsized IPO. Sionna's stock surged nearly 40% on its debut and is trading under the ticker "SION" on the Nasdaq. https://lnkd.in/ePUK_QeD

We are thrilled to announce our co-lead investment in Helicore Biopharma's $65 million Series A financing round. Helicore is pioneering the development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists, targeting obesity and related conditions. Its lead candidate, HCR-188, is set to enter first-in-human clinical studies this year. We look forward to supporting Helicore and its platform for improved efficacy, dosing, and tolerability for obesity medicines. https://lnkd.in/eFff6wXf

We are pleased to support Verdiva Bio by participating in its $411M Series A financing. Verdiva is a clinical-stage company focusing on the development of innovative therapies for obesity and other cardiometabolic disorders and other complications. We look forward to working with Verdiva as it advances its lead program, VRB-101, an oral weekly GLP-1 receptor agonist peptide, and its near-clinical stage amylin agonists portfolio with oral and injectable options. Congratulations to the Verdiva team Khurem Farooq, Mark Pruzanski, MA, MD, and Mohamed Eid, MD, MSc, MHA, and our team, Ran Geng, Vivek Sivathanu PhD, Mona Ashiya, and Carl Gordon, on this exciting launch! https://lnkd.in/esdDgB_4

Congrats to our team and our portfolio company, Laxmi Dental Limited, on their successful IPO on both the Bombay Stock Exchange and the National Stock Exchange of India! The IPO was highly subscribed, and the stock was listed at a premium of 27% over the IPO price. Laxmi Dental is India’s only end-to-end integrated dental products company and plans to use the IPO capital primarily to fuel further growth. https://lnkd.in/epfzgEZP

We are proud to announce that we are partnering with Windward Bio by participating in its $200 million Series A financing to develop a phase 2-ready long-acting anti-TSLP antibody. Together, we aim to create a best-in-class potential in treating asthma and COPD. https://lnkd.in/eKiwiNaM

Exciting news from our portfolio company, Scorpion Therapeutics! Eli Lilly and Company announced the acquisition of Scorpion’s PI3Kα inhibitor program, STX-478, for up to $2.5 billion, including upfront and milestone payments. Congratulations to Adam Friedman, MD, PhD, Gary D. Glick, and the Scorpion team for this incredible milestone. We’re proud to have supported Scorpion's mission to advance precision oncology and look forward to their next chapter as they spin out a new company focused on non-PI3Kα assets. https://lnkd.in/eeaH8gmh

Thanks to Endpoints News for sharing the exciting news about our portfolio company iECURE, inc., and their potentially curative therapy for a devasting orphan disease, OTC deficiency. OrbiMed co-founded iEcure, working closely with Jim Wilson, to focus on gene insertion therapies to treat pediatric orphan diseases and other conditions. We’re thrilled to see this early progress and look forward to getting this critical therapy developed for patients. https://lnkd.in/e2-iF_j2